7 August 2019 in Science Translational Medicine
AOAhuva Odenheimer-Bergman
+14
Longitudinal analysis of circulating tumor DNA (ctDNA) has shown promise for monitoring treatment response. However, most current methods lack adequate sensitivity for residual disease detection during or after completion of treatment in patients with nonmetastatic cancer. To address this gap and to improve sensitivity for minute quantities of residual tumor DNA in plasma, we have developed targeted digital sequencing (TARDIS) for multiplexed analysis of patient-specific cancer mutations. In reference samples, by simultaneously analyzing 8 to 16 known mutations, TARDIS achieved 91 and 53% sensitivity at mutant allele fractions (AFs) of 3 in 104 and 3 in 105, respectively, with 96% specificity, using input DNA equivalent to a single tube of blood. We successfully analyzed up to 115 mutations per patient in 80 plasma samples from 33 women with stage I to III breast cancer. Before treatment, TARDIS detected ctDNA in all patients with 0.11% median AF. After completion of neoadjuvant therapy, ctDNA concentrations were lower in patients who achieved pathological complete response (pathCR) compared to patients with residual disease (median AFs, 0.003 and 0.017%, respectively, P = 0.0057, AUC = 0.83). In addition, patients with pathCR showed a larger decrease in ctDNA concentrations during neoadjuvant therapy. These results demonstrate high accuracy for assessment of molecular response and residual disease during neoadjuvant therapy using ctDNA analysis. TARDIS has achieved up to 100-fold improvement beyond the current limit of ctDNA detection using clinically relevant blood volumes, demonstrating that personalized ctDNA tracking could enable individualized clinical management of patients with cancer treated with curative intent.
1 December 2018 in Computerized Medical Imaging and Graphics
1 February 2018 in Seminars in Ultrasound, CT and MRI
1 June 2017 in American Journal of Roentgenology
OBJECTIVE. The purpose of this article is to discuss whether the sensitivity and specificity of contrast-enhanced digital mammography (CEDM) render it a viable diagnostic alternative to breast MRI. CONCLUSION. That CEDM couples low-energy images (comparable to the diagnostic quality of standard mammography) and subtracted contrast-enhanced mammograms make it a cost-effective modality and a realistic substitute for the more costly breast MRI.
22 April 2019 in IEEE Journal of Biomedical and Health Informatics
Image synthesis is a novel solution in precision medicine for scenarios where important medical imaging is not otherwise available. Convolutional neural network is an ideal model for this task because of its powerful learning capabilities through the large number of layers and trainable parameters. In this research, we propose a new architecture of Residual Inception Encoder-Decoder Neural Network (RIED-Net) to learn the nonlinear mapping between the input images and targeting output images. To evaluate the validity of the proposed approach, it is compared with 2 models from the literature: sCT-DCNN and Shallow CNN, using both an institutional mammogram dataset from Mayo Clinic Arizona and a public neuroimaging dataset from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Experimental results show that the proposed RIED-Net outperforms the two models on both datasets significantly in terms of structural similarity index (SSIM), mean absolute percent error (MAPE), and peak signal to noise ratio (PSNR).
1 January 2018 in European Journal of Radiology